Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025

November 6, 2025
Read More
October 22, 2025

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development

Read More
September 19, 2025

Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups

Read More
July 10, 2025

Comments from Dr. Shefali Agarwal, President and CEO, on Agreement with Novartis

Read More
Learn More

Publications

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

Clin Transl Sci., 2025

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Clin Transl Sci., 2024

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

International Neurology & Brain Disorders Conference, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Journal of Intensive Medicine, 2024